Abstract:Immune checkpoint inhibitor agents have been widely explored as cancer immunotherapies, among which PD-1 blockade is most commonly used to treat several types of cancer. The outcome of such therapies is dependent on factors such as tumor immunogenicity and immune contexture, as well as intrinsic and adaptive resistance pathways. Among other modalities in immunotherapy, IL-2 was the first approved treatment for metastatic melanoma and RCC. Despite its long term efficacy, its use is limited by dose related toxicities, including capillary leak syndrome. The short half-life of IL-2 and the preferential targeting of Tregs, signifies that it has to be administered at high doses to reach CD8+ T cells, exacerbating the associated systemic toxicities. These considerable limitations have bolstered research efforts to identify safer ways to administer IL-2 without compromising its efficacy. PD1-IL2v was developed to deliver IL2Rβγ agonism to PD-1+ T cells, by combining a bivalent aPD-1 antibody and a mutated IL-2 moiety with abolished binding to IL-2Rα. The high affinity aPD-1 arm enables the preferential delivery of IL2v to PD-1+ T cells, including stem-like CD8+ T cells: a PD-1+TCF-1+ subset responsible for the clinical response to aPD-1 therapy and better disease prognosis. PD1-IL2v has shown superior efficacy over combinations of aPD-1 and stroma-targeted IL-2v in previously tested preclinical mouse tumor models, such as Panc02,B16-F10-OVA,MCA-205 and Rip-Tag5, however responses in MC38 and KPC-4662 were heterogeneous. One of the major hurdles with the usage of immunotherapies is determining which patients will respond to the therapy and to identify pre- or on- treatment biomarkers that associate with response or lack of response. In this study, we used YUMMER1.7(R)*, a mouse melanoma model bearing patient relevant driver mutations and a high tumor mutational burden similar to that found in human melanomas. PD1-IL2v treatment showed better tumor growth inhibition activity compared to aPD-1 and FAP-IL2v monotherapies. Ex-vivo re-stimulation of tumor infiltrating and tumor draining lymph node lymphocytes from PD1-IL2v treated mice showed activation of highly cytotoxic tumor-specific T cells.Although these cells were proven to be functional, based on their expression of TNFα and GrzB secretion, the tumors escaped control in treated mice around day 21. To assess potential combination partners able to overcome resistance to PD1-IL2v monotherapy, we tested PD1-IL2v with aPD-L1 and aCTLA-4. In addition, we are performing RNAseq to understand the transcriptional profile induced by the treatment and how this shapes response in the YUMMER1.7(R) model. Furthermore, to relate these findings to the clinical outcome of PD1-IL2v treated patients, we are analyzing ex-vivo PBMCs and TILs isolated from CPI naive and experienced solid tumor patients. Our ultimate aim is to identify a unique set of biomarkers and to translate this to clinical settings in order to aid in patient enrichment.*The YUMMER1.7 clone used in this project was generated in- house at Roche (R) Citation Format: Amrita Manchala, Eleni Maria Varypataki, Maria Karagianni, Elzbieta Gralinska, Christian Münz, Christian Klein, Jehad Charo, Laura Codarri Deak. Identifying response factors to PD1-IL2v therapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B004.

PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells

Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1

Pd-1 Blockade Restores Impaired Function Of Ex Vivo Expanded Cd8+T Cells And Enhances Apoptosis In Mismatch Repair Deficient Epcacam+Pd-L1+Cancer Cells

Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb

1236 Selective Delivery of Low-Affinity IL-2 to PD-1+ T Cells Rejuvenates Antitumor Immunity with Reduced Toxicity

Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

PD-1 blockade induces responses by inhibiting adaptive immune resistance

PD-1 controls differentiation, survival, and TCR affinity evolution of stem-like CD8+ T cells

PD-1 Blockade Augments Humoral Immunity Through ICOS-mediated CD4+ T Cell Instruction.

Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy

Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells

Abstract B004: Identifying response factors to PD1-IL2v therapy

PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy